Cumberbatch M, Bhushan M, Dearman R J, Kimber I, Griffiths C E M
Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, UK.
Clin Exp Immunol. 2003 May;132(2):352-9. doi: 10.1046/j.1365-2249.2003.02146.x.
In mice, the roles of cytokines in the initiation of epidermal Langerhans' cell (LC) migration are well documented; however, the mechanism of this response in humans is less well defined. The purpose of the present investigation was to examine the contribution of interleukin (IL)-1beta to human epidermal LC migration and to define further the mechanisms of this response. We demonstrate here that homologous recombinant IL-1beta administered intradermally to healthy human volunteers provides a stimulus for LC migration, with significant (P < 0.01) reductions in LC densities being observed at both 2 h and 4 h following treatment. At the later time-point of 4 h, injection of IL-1beta was also accompanied by activation of those LC remaining in the epidermis. Analysis of fluid aspirated from suction blisters formed at injection sites revealed significant (P < 0.01) tumour necrosis factor (TNF)-alpha production (2.99 +/- 1.18 pg TNF-alpha/mg protein; mean +/- s.d. of n = 10) in response to IL-1beta treatment compared with saline control injections (0.90 +/- 1.05 pg TNF-alpha/mg protein). Prior topical application of human recombinant lactoferrin (LF), an iron-binding protein found in exocrine secretions and skin, inhibited IL-1beta-mediated LC migration and also compromised the production of TNF-alpha protein as measured in suction blister fluids derived from each of the treatment sites. Taken together, these data demonstrate that IL-1beta is associated with both the stimulation of human epidermal LC migration and local TNF-alpha production. Topical treatment with LF compromises both these responses. These data suggest that topical LF may potentially represent a novel therapeutic in the treatment of skin inflammation where TNF-alpha is an important mediator.
在小鼠中,细胞因子在表皮朗格汉斯细胞(LC)迁移起始过程中的作用已有充分记载;然而,人类中这种反应的机制尚不太明确。本研究的目的是探讨白细胞介素(IL)-1β对人类表皮LC迁移的作用,并进一步明确这种反应的机制。我们在此证明,对健康人类志愿者进行皮内注射同源重组IL-1β可刺激LC迁移,在治疗后2小时和4小时均观察到LC密度显著(P<0.01)降低。在4小时这个较晚的时间点,注射IL-1β还伴随着表皮中剩余LC的激活。对注射部位形成的抽吸水疱中吸出的液体进行分析发现,与生理盐水对照注射(0.90±1.05 pg TNF-α/毫克蛋白质)相比,IL-1β治疗后肿瘤坏死因子(TNF)-α产生显著(P<0.01)(2.99±1.18 pg TNF-α/毫克蛋白质;n = 10的平均值±标准差)。事先局部应用人重组乳铁蛋白(LF),一种在外分泌液和皮肤中发现的铁结合蛋白,可抑制IL-1β介导的LC迁移,并损害从每个治疗部位的抽吸水疱液中测得的TNF-α蛋白的产生。综上所述,这些数据表明IL-1β与人类表皮LC迁移的刺激以及局部TNF-α的产生均有关。LF局部治疗会损害这两种反应。这些数据表明,局部应用LF可能代表一种治疗皮肤炎症的新型疗法,其中TNF-α是一种重要的介质。